Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Next-Generation Sequencing in Medicine (Upcoming)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI115925

Cell retargeting by bispecific monoclonal antibodies. Evidence of bypass of intratumor susceptibility to cell lysis in human melanoma.

P Nisticò, R Mortarini, L B De Monte, A Mazzocchi, M Mariani, F Malavasi, G Parmiani, P G Natali, and A Anichini

Laboratorio di Immunologia, Istituto Tumori Regina Elena, Rome, Italy.

Find articles by Nisticò, P. in: JCI | PubMed | Google Scholar

Laboratorio di Immunologia, Istituto Tumori Regina Elena, Rome, Italy.

Find articles by Mortarini, R. in: JCI | PubMed | Google Scholar

Laboratorio di Immunologia, Istituto Tumori Regina Elena, Rome, Italy.

Find articles by De Monte, L. in: JCI | PubMed | Google Scholar

Laboratorio di Immunologia, Istituto Tumori Regina Elena, Rome, Italy.

Find articles by Mazzocchi, A. in: JCI | PubMed | Google Scholar

Laboratorio di Immunologia, Istituto Tumori Regina Elena, Rome, Italy.

Find articles by Mariani, M. in: JCI | PubMed | Google Scholar

Laboratorio di Immunologia, Istituto Tumori Regina Elena, Rome, Italy.

Find articles by Malavasi, F. in: JCI | PubMed | Google Scholar

Laboratorio di Immunologia, Istituto Tumori Regina Elena, Rome, Italy.

Find articles by Parmiani, G. in: JCI | PubMed | Google Scholar

Laboratorio di Immunologia, Istituto Tumori Regina Elena, Rome, Italy.

Find articles by Natali, P. in: JCI | PubMed | Google Scholar

Laboratorio di Immunologia, Istituto Tumori Regina Elena, Rome, Italy.

Find articles by Anichini, A. in: JCI | PubMed | Google Scholar

Published September 1, 1992 - More info

Published in Volume 90, Issue 3 on September 1, 1992
J Clin Invest. 1992;90(3):1093–1099. https://doi.org/10.1172/JCI115925.
© 1992 The American Society for Clinical Investigation
Published September 1, 1992 - Version history
View PDF
Abstract

Intratumor heterogeneity for susceptibility to cytotoxic T lymphocytes (CTL)-mediated lysis represents a major obstacle to cancer adoptive immunotherapy. To overcome the heterogeneity observed in terms of susceptibility of target cells to cell-mediated lysis, in this study we used two purified bispecific monoclonal antibodies (bsmAbs) that recognize molecules expressed by cytotoxic effector cells (CD3 and IgG Fc receptorial molecules), as well as one high molecular weight melanoma-associated antigen (HMW-MAA). The ability of these reagents to enhance or induce a relevant in vitro cytotoxic activity by a CTL clone (CTL 49) isolated from PBL of a melanoma patient was tested on a large panel of autologous and allogeneic melanoma cell lines and clones. Functional studies revealed that the CTL 49 clone lysed all the HMW-MAA+ tumor lines in the presence of bsmAbs and that these reagents affected the target lysis in a cooperative fashion. The effectiveness of bsmAbs in overcoming the heterogeneous susceptibility of human melanoma cells to cell-mediated lysis may find practical implications in cancer adoptive immunotherapy.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1093
page 1093
icon of scanned page 1094
page 1094
icon of scanned page 1095
page 1095
icon of scanned page 1096
page 1096
icon of scanned page 1097
page 1097
icon of scanned page 1098
page 1098
icon of scanned page 1099
page 1099
Version history
  • Version 1 (September 1, 1992): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts